MAIA Biotechnology, Inc.
NYSE · Healthcare · Pharmaceutical Preparations · Chicago, IL
MAIA chart
What traders are saying about $MAIA
Latest postsMAIA Biotechnology, Inc. news
- MAIA Biotechnology, Inc. Estimates – AMEX:MAIA
TradingView ·
- MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer
Yahoo Finance ·
- MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal
Yahoo Finance ·
- MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer
Yahoo Finance ·
- MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial
Yahoo Finance ·
- MAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO
Yahoo Finance ·
- MAIA Biotechnology Delivers Oral and Poster Presentations Showcasing Next-Generation Telomere-Targeting Cancer Therapies at IRT 2026
Yahoo Finance ·
- Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)
Yahoo Finance ·
- MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial
Yahoo Finance ·
- MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer
Yahoo Finance ·
- MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University
Yahoo Finance ·
- MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial
Yahoo Finance ·
MAIA Biotechnology, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | $0 | $0 | $0 |
| Net income | -$22.4M | -$23.3M | – | – |
| Diluted EPS | $-0.70 | $-1.05 | $-1.49 | $-1.75 |
| Total assets (year end) | $9.7M | $10.2M | $7.6M | $12.0M |
| Cash and equivalents (year end) | $0 | $0 | $0 | $0 |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About MAIA Biotechnology, Inc.
- Ticker
- MAIA (NYSE)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Chicago, IL
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1878313
Frequently asked questions
What exchange is MAIA Biotechnology, Inc. listed on?
MAIA Biotechnology, Inc. trades on the NYSE under the ticker symbol MAIA.
What industry is MAIA Biotechnology, Inc. in?
MAIA Biotechnology, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is MAIA Biotechnology, Inc. headquartered?
MAIA Biotechnology, Inc.'s business address on file with the SEC is in Chicago, IL.
When does MAIA Biotechnology, Inc.'s fiscal year end?
MAIA Biotechnology, Inc.'s fiscal year ends on December 31.
How much revenue did MAIA Biotechnology, Inc. report?
MAIA Biotechnology, Inc. reported $0 in revenue for calendar year 2024, according to its SEC filings.